Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCL

Video

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma (MCL).

The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are active in relapsed/refractory MCL and have shown significant response rates; however, patients continue to relapse on these regimens, explains Andreadis. The median duration of response for BTK inhibitors is 1.5 years. Therefore, new therapies are necessary for this patient population, says Andreadis.

The emergence of CAR T-cell therapy has shown significant benefit in patients with relapsed/refractory MCL who are heavily pretreated. The CAR T-cell therapies lisocabtagene maraleucel (JCAR017) and axicabtagene ciloleucel (Yescarta), according to Andreadis, are showing 70% to 90% response rates and 50% to 60% complete response rates in patients with relapsed/refractory disease. Andreadis believes CAR T-cell therapy will be significant in the future of MCL treatment.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.